Management strategies in the treatment of neonatal and pediatric gastroenteritis

Infection and Drug Resistance

Volumn 6, Issue , 2013, Pages 133-161

  Ciccarelli, Simona ^a   Stolfi, Ilaria ^a   Caramia, Giuseppe ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Ospedale Pediatrico G Salesi   (Italy)

Author keywords

Acute infective gastroenteritis; Children; Diarrhea; Oral rehydration solution; Probiotics; Vomiting

Indexed keywords

ACETORPHAN; ALBENDAZOLE; AMPHOTERICIN B; ANTIINFECTIVE AGENT; AURANOFIN; AZITHROMYCIN; CASPOFUNGIN; CEFALOTIN; CEPHALOSPORIN; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; FLUCONAZOLE; IVERMECTIN; MEBENDAZOLE; METRONIDAZOLE; MICAFUNGIN; NITAZOXANIDE; ONDANSETRON; ORAL REHYDRATION SOLUTION; PAROMOMYCIN; PLACEBO; PLECONARIL; PROBIOTIC AGENT; TINIDAZOLE; ZINC;

AMEBIASIS; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; CANDIDIASIS; DEHYDRATION; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; ENTEROVIRUS INFECTION; FECES ANALYSIS; GASTROENTERITIS; HAND WASHING; HOSPITALIZATION; HUMAN; LACTOBACILLUS REUTERI; LACTOBACILLUS RHAMNOSUS; MORBIDITY; MORTALITY; MYCOSIS; NAUSEA AND VOMITING; NEWBORN DISEASE; NEWBORN INFECTION; NONHUMAN; ORAL REHYDRATION THERAPY; PROTOZOAL INFECTION; ROTAVIRUS; SACCHAROMYCES BOULARDII; SHIGELLA; VIBRIO CHOLERAE; VIRAL GASTROENTERITIS;

EID: 84886811567     PISSN: 11786973     EISSN: None     Source Type: Journal    
DOI: 10.2147/IDR.S12718     Document Type: Article

References (193)

1. Pieścik-Lech M, Shamir R, Guarino A, Szajewska H. Review article: the management of acute gastroenteritis in children. Aliment Pharmacol Ther. 2013;37:289-303.
2. Guarino A, Dupont C, Gorelov AV, et al. The management of acute diarrhea in children in developed and developing areas: from evidence base to clinical practice. Expert Opin Pharmacother. 2012;13:17-26.
3. World Health Organization. Diarrhoea. Available from: http://www.who.int/topics/diarrhoea/en. Accessed April 7, 2013.
4. National Collaborating Centre for Women's and Children's Health. {Eth}iarrhea and Vomiting Caused by Gastroenteritis: Diagnosis, Assessment and Management in Children Younger Than 5 Years. London: RCOG Press; 2009. Available from: http://www.nice.org.uk/nicemedia/pdf/CG84FullGuideline.pdf. Accessed March 31, 2012.
5. Chow CM, Leung AK, Hon KL. Acute gastroenteritis: from guidelines to real life. Clin Exp Gastroenterol. 2010;3:97-112.
6. Guarino A, Albano F, Ashkenazi S, et al. European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe. J Pediatr Gastroenterol Nutr. 2008;46 Suppl 2:S81-S122.
7. Forster J, Guarino A, Parez N, et al. Hospital-based surveillance to estimate the burden of rotavirus gastroenteritis among European children younger than 5 years of age. Pediatrics. 2009;123:e393-e400.
8. Albano F, Bruzzese E, Bella A, et al. Rotavirus and not age determines gastroenteritis severity in children: a hospital-based study. Eur J Pediatr. 2007;166:241-247.
9. Parashar UD, Gibson CJ, Bresee JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerg Infect Dis. 2006;12:304-306.
10. De Rougemont A, Kaplon J, Pillet S, et al. Molecular and clinical characterization of rotavirus from diarrheal infants admitted to pediatric emergency units in France. Pediatr Infect Dis J. 2011;30:118-124.
11. Palumbo E, Branchi M, Malorgio C, et al. Diarrhea in children: etiology and clinical aspects. Minerva Pediatr. 2010;62: 347-351.
12. Kinnula S, Buettcher M, Tapiainen T, et al. Hospital-associated infections in children: a prospective post-discharge follow-up survey in three different paediatric hospitals. J Hosp Infect. 2012;80:17-24.
13. Wittenberg DF. Management guidelines for acute infective diarrhoea/ gastroenteritis in infants. S Afr Med J. 2012;102:104-107.
14. Ganguli K, Walker WA. Probiotics in the prevention of necrotizing enterocolitis. J Clin Gastroenterol. 2011;45 Suppl:S133-S138.
15. Vandenplas Y, Veereman-Wauters G, et al. Probiotics and probiotics in prevention and treatment of diseases in infants and children. Pediatr (Rio J). 2011;87(4):292-300. English, Portuguese.
16. Kligler B, Hanaway P, Cohrssen A. Probiotics in children. Pediatr Clin North Am. 2007;54:949-967.
17. Quigley MA, Kelly YJ, Sacker A. Breast-feeding and hospitalization for diarrhoeal and respiratory infection in the United Kingdom Millenium Cohort Study. Pediatrics. 2007;119:e837-e842.
18. Quigley MA, Cumberland P, Cowden JM, et al. How protective is breast-feeding against diarrheal disease in infants in 1990s England? A case-control study. Arch Dis Child. 2006;91:245-250.
19. Satyanarayana L, Kumar S. Water supplementation in exclusively breastfed infants during summer in the tropics. Lancet. 1991;337: 929-933.
20. Williams HG. And not a drop to drink-why water is harmful for newborns. Breastfeed Rev. 2006;14:5-9.
21. Mansour AM, Abd Elkhalek R, et al. Burden of Aeromonas hydrophilaassociated diarrhea among children younger than 2 years in rural Egyptian community. J Infect Dev Ctries. 2012;6:842-846.
22. Bhutta ZA. Acute gastroenteritis in children. In Kliegman RM, Behrman RE, Jenson HB, Stanton BF, editors. Nelson's Textbook of Pediatrics, 18th ed. Philadelphia: Saunders; 2007.
23. Mortensen NP, Schiellerup P, Boisen N, et al. The role of Campylobacter jejuni cytolethal distending toxin in gastroenteritis: toxin detection, antibody production, and clinical outcome. APMIS. 2011;119: 626-634.
24. McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology. 2009;32:150-163.
25. Jacobs BC, Van Belkum A, Endtz HP. Guillain-Barré syndrome and Campylobacter infection. In: Nachamkin I, Szymanski CM, Blaser MJ, editors. Campylobacter, 3rd ed. Washington: American Society for Microbiology; 1998:245-261.
26. Poropatich KO, Walker CL, Black RE. Quantifying the association between Campylobacter infection and Guillain-Barré syndrome: a systematic review. J Health Popul Nutr. 2010;28:545-552.
27. Alam S, Mushtaq M. Antibiotic associated diarrhea in children. Indian Pediatr. 2009;46:491-496.
28. Zilberberg MD, Shorr AF, Kollef MH. Increase in Clostridium difficilerelated hospitalizations among infants in the United States, 2000-2005. Pediatr Infect Dis J. 2008;27:1111-1113.
29. Kim J, Smathers SA, Prasad P, Leckerman KH, Coffin S, Zaoutis T. Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001-2006. Pediatrics. 2008;122:1266-1270.
30. Luna RA, Boyanton BL Jr, Mehta S, et al. Rapid stool-based diagnosis of Clostridium difficile infection by real-time PCR in a children's hospital. J Clin Microbiol. 2011;49:851-857.
31. Baron S, editor. Medical Microbiology, 4th ed. Galveston (TX): University of Texas Medical Branch at Galveston; 1996. Available from: http://www.ncbi.nlm.nih.gov/books/NBK7627. Accessed April 7, 2013.
32. Chang JY, Shin SM, Chun J, Lee JH, Seo JK. Pyrosequencing-based molecular monitoring of the intestinal bacterial colonization in preterm infants. J Pediatr Gastroenterol Nutr. 2011;53:512-519.
33. Käppeli U, Hächler H, Giezendanner N, Beutin L, Stephan R. Human infections with non-O157 Shiga toxin-producing Escherichia coli, Switzerland, 2000-2009. Emerg Infect Dis. 2011;17:180-185.
34. Karmali MA, Steele BT, Petric M, Lim C. Sporadic cases of haemolyticuraemic syndrome associated with faecal cytotoxin and cytotoxinproducing Escherichia coli in stools. Lancet. 1983;1:619-620.
35. Riley LW, Remis RS, Helgerson SD, et al. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Engl J Med. 1983;308: 681-685.
36. Peacock E, Jacob VW, Fallone SM. Escherichia coli O157:H7: etiology, clinical features, complications, and treatment. Nephrol Nurs J. 2001;28:547-550.
37. Clarke SC. Diarrhoeagenic Escherichia coli-an emerging problem? Diagn Microbiol Infect Dis. 2001;41:93-98.
38. Vally H, Hall G, Dyda A, et al. Epidemiology of Shiga toxin producing Escherichia coli in Australia, 2000-2010. BMC Public Health. 2012;12:63.
39. Bettleheim K. The non-O157 Shiga toxigenic (verotocytotoxigenic) Escherichia coli: under-rated pathogens. Crit Rev Microbiol. 2007;33:67-87.
40. Griffin PM, Tauxe RV. The epidemiology of infections caused by Escherichia coli O157:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome. Epidemiol Rev. 1991;13:60-98.
41. [No authors listed]. The community summary report on trends and sources of zoonoses and zoonotic agents in the European Union in 2008. EFSA J. 2010;10:1496.
42. Gould LH, Bopp C, Strockbine N, et al. Recommendations for diagnosis of shiga toxin-producing Escherichia coli infections by clinical laboratories. MMWR Recomm Rep. 2009;58:1-14.
43. Perry S, Sanchez L, Yang S, et al. Helicobacter pylori and risk of gastroenteritis. J Infect Dis. 2004;190: 303-310.
44. Sullivan PB, Thomas JE, Wight DG, et al. Helicobacter pylori in Gambian children with chronic diarrhoea and malnutrition. Arch Dis Child. 1990;65:189-191.
45. Clemens J, Albert MJ, Rao M, et al. Impact of infection by Helicobacter pylori on the risk and severity of endemic cholera. J Infect Dis. 1995;171:1653-1656.
46. Bhan MK, Bahl R, Sazawal S, et al. Association between Helicobacter pylori infection and increased risk of typhoid fever. J Infect Dis. 2002;186:1857-1860.
47. Passaro DJ, Taylor DN, Meza R, et al. Acute Helicobacter pylori infection is followed by an increase in diarrheal disease among Peruvian children. Pediatrics. 2001;108:E87.
48. Isenbarger DW, Bodhidatta L, Hoge CW, et al. Prospective study of the incidence of diarrheal disease and Helicobacter pylori infection among children in an orphanage in Thailand. Am J Trop Med Hyg. 1998;59:796-800.
49. Pütsep K, Brändén CI, Boman HG, Normark S. Antibacterial peptide from H. pylori. Nature. 1999;398:671-672.
50. Rothenbacher D, Blaser MJ, Bode G, Brenner H. Inverse relationship between gastric colonization of Helicobacter pylori and diarrheal illnesses in children: results of a population-based cross-sectional study. J Infect Dis. 2000;182:1446-1449.
51. Sachs G, Weeks DL, Melchers K, Scott DR. The gastric biology of Helicobacter pylori. Annu Rev Physiol. 2003;65:349-369.
52. Dore MP, Fanciulli G, Tomasi PA, et al. Gastrointestinal symptoms and Helicobacter pylori infection in school-age children residing in Porto Torres, Sardinia, Italy. Helicobacter. 2012;17:369-373.
53. Kamga HL, Assob JC, Nsagha DS, et al. Epidemiological studies on proteeae isolates from clinical specimens in the Laquintinie Hospital in Douala, Cameroon. Afr J Clin Exper Microbiol. 2012;13:112-120.
54. Crivaro V, Di Popolo A, Caprio A, et al. Pseudomonas aeruginosa in a neonatal intensive care unit: molecular epidemiology and infection control measures. BMC Infect Dis. 2009;9:70.
55. Caramia G, Ruffini E, Salvatori P. Infectious gastroenteritis. From: Neonatal Infectious Diseases Study Group of the Italian Society of Neonatology. Manual of Neonatal Infectious Diseases. Milan: Biomedia. 2009.
56. Wu T, Grassel C, Levine MM, et al. Live attenuated Shigella dysenteriae type 1 vaccine strains overexpressing shiga toxin B subunit. Infect Immun. 2011;79:4912-4922.
57. El Qouqa IA, El Jarou MA, Samaha AS, et al. Yersinia enterocolitica infection among children aged less than 12 years: a case-control study. Int J Infect Dis. 2011;15:e48-e53.
58. Batzilla J, Heesemann J, Rakin A. The pathogenic potential of Yersinia enterocolitica 1A. Int J Med Microbiol. 2011;301:556-561.
59. Dennehy PH. Viral gastroenteritis in children. Pediatr Infect Dis J. 2011;30:63-64.
60. Pawlowski SW, Warren CA, Guerrant R. Diagnosis and treatment of acute or persistent diarrhea. Gastroenterology. 2009;136: 1874-1886.
61. Caramia G, Ruffini E, Fanos V. Infections and Pediatric Pharmacotheray, 4th ed. Milan: Biomedia; 2007.
62. Goodgame RW. Viral infections of the gastrointestinal tract. Curr Gastroenterol Rep. 1999;1:292-300.
63. Rimoldi SG, Stefani F, Pagani C, et al. Epidemiological and clinical characteristics of pediatric gastroenteritis associated with new viral agents. Arch Virol. 2011;156:1583-1589.
64. Tokarz R, Firth C, Madhi SA, et al. Worldwide emergence of multiple clades of enterovirus 68. J Gen Virol. 2012;93:1952-1958.
65. Chitambar S, Gopalkrishna V, Chhabra P, et al. Diversity in the enteric viruses detected in outbreaks of gastroenteritis from Mumbai, Western India. Int J Environ Res Public Health. 2012;9:895-815.
66. Li J, Lin C, Qu M, et al. Excretion of enterovirus 71 in persons infected with hand, foot and mouth disease. Virol J. 2013;10:31.
67. Wildenbeest JG, van den Broek PJ, Benschop KS, et al. Pleconaril revisited: clinical course of chronic enteroviral meningoencephalitis after treatment correlates with in vitro susceptibility. Antivir Ther. 2012;17:459-466.
68. Zhu FC, Liang ZL, Li XL, et al. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet. Epub January 23, 2013.
69. Proenca-Modena JL, Martinez M, Amarilla AA, et al. Viral load of human bocavirus-1 in stools from children with viral diarrhoea in Paraguay. Epidemiol Infect. Epub February 21, 2013.
70. Risku M, Lappalainen S, Räsänen S, Vesikari T. Detection of human coronaviruses in children with acute gastroenteritis. J Clin Virol. 2010;48:27-30.
71. Iritani N, Seto Y, Kubo H, et al. Prevalence of Norwalk-like virus infecions in cases of viral gastroenteritis among children in Osaka City, Japan. J Clin Microbiol. 2003;41:1756-1759.
72. Medici MC, Martinelli M, Arcangeletti MC, et al. Epidemiological aspects of human rotavirus infection in children hospitalized with acute gastroenteritis in an area of northern Italy. Acta Biomed. 2004;75:100-106.
73. Moreno-Espinosa S, Farkas T, Jiang X. Human caliciviruses and pediatric gastroenteritis. Semin Pediatr Infect Dis. 2004;15:237-245.
74. Hansman GS, Saito H, Shibata C, et al. Outbreak of gastroenteritis due to sapovirus. J Clin Microbiol. 2007;45:1347-1349.
75. Oka T, Mori K, Iritani N, et al. Human sapovirus classification based on complete capsid nucleotide sequences. Arch Virol. 2012;157: 349-352.
76. Burián Z, Szabó H, Székely G, et al. Detection and follow-up of torque teno midi virus ("small anelloviruses") in nasopharyngeal aspirates and three other human body fluids in children. Arch Virol. 2011;156: 1537-1541.
77. Jelcic I, Hotz-Wagenblatt A, Hunziker A, et al. Isolation of multiple TT virus genotypes from spleen biopsy tissue from a Hodgkin's disease patient: genome reorganization and diversity in the hypervariable region. J Virol. 2004;78:7498-7507.
78. Peng YH, Nishizawa T, Takahashi M, et al. Analysis of the entire genomes of thirteen TT virus variants classifiable into the fourth and fifth genetic groups, isolated from viremic infants. Arch Virol. 2002;147:21-41.
79. Kekarainen T, Segalés J. Torque teno virus infection in the pig and its potential role as a model of human infection. Vet J. 2009;180: 163-168.
80. Friedman M, Ramsay DB, Borum ML. An unusual case report of small bowel Candida overgrowth as a cause of diarrhea and review of the literature. Dig Dis Sci. 2007;52:679-680.
81. Bond S, Stewart DL, Bendon RW. Invasive Candida enteritis of the newborn. J Pediatr Surg. 2000;35:1496-1498.
82. Ali GY, Algohary EH, Rashed KA, Alm Kh. Prevalence of Candida colonization in preterm newborns and VLBW in neonatal intensive care unit: role of maternal colonization as a risk factor in transmission of disease. J Matern Fetal Neonatal Med. 2012;25: 789-795.
83. Manzoni P, Mostert M, Jacqz-Aigrain E, S Fa Candida colonization in the nursery. J Pediatr (Rio J). 2012;88:187-190.
84. Zaoutis T, Walsh TJ. Antifungal therapy for neonatal candidiasis. Curr Opin Infect Dis. 2007;20:592-597.
85. Benjamin DK Jr, Smith PB, Arrieta A, et al. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther. 2010;87:93-99.
86. Allen U, Richardson S, McGuire W, et al. Pediatric antifungal therapy. Part II: neonatal infections. Minerva Pediatr. 2010;62:71-78.
87. Hsieh E, Smith PB, Jacqz-Aigrain E, et al. Neonatal fungal infections: when to treat? Early Hum Dev. 2012;88 Suppl 2:S6-S10.
88. Kaufman DA."Getting to zero": preventing invasive Candida infections and eliminating infection-related mortality and morbidity in extremely preterm infants. Early Hum Dev. 2012;88 Suppl 2:S45-S49.
89. Leibovitz E. Strategies for the prevention of neonatal candidiasis. Pediatr Neonatol. 2012;53:83-89.
90. Liévin-Le Moal V. Dysfunctions at human intestinal barrier by water-borne protozoan parasites: lessons from cultured human fully-differentiated colon cancer cell lines. Cell Microbiol. Epub February 26, 2013.
91. Elgun G, Koltas IS. Investigation of Cryptosporidium spp. antigen by ELISA method in stool specimens obtained from patients with diarrhea. Parasitol Res. 2011;108:395-397.
92. Ali SA, Hill DR. Giardia intestinalis. Curr Opin Infect Dis. 2003;16: 453-460.
93. Nkrumah B, Nguah SB. Giardia lamblia: a major parasitic cause of childhood diarrhoea in patients attending a district hospital in Ghana. Parasit Vectors. 2011;4:163.
94. Samie A, Obi LC, Bessong PO, Stroup S, Houpt E, Guerrant RL. Prevalence and species distribution of E. histolytica and E. dispar in the Venda region, Limpopo, South Africa. Am J Trop Med Hyg. 2006;75: 565-571.
95. Haque R, Mondal D, Karim A, et al. Prospective case-control study of the association between common enteric protozoal parasites and diarrhea in Bangladesh. Clin Infect Dis. 2009;48:1191-1197.
96. Norsarwany M, Abdelrahman Z, Rahmah N, et al. Symptomatic chronic strongyloidiasis in children following treatment for solid organ malignancies: case reports and literature review. Trop Biomed. 2012;29:479-488.
97. Keske LA, Letizia M. Clostridium difficile infection: essential information for nurses. Medsurg Nurs. 2010;19:329-332.
98. Pereira LA, Raboni SM, Nogueira MB, et al. Rotavirus infection in a tertiary hospital: laboratory diagnosis and impact of immunization on pediatric hospitalization. Braz J Infect Dis. 2011;15:215-219.
99. Shima A, Hinenoya A, Asakura M, et al. Prevalence of Providencia strains among children with diarrhea in Japan. Jpn J Infect Dis. 2012;65:545-547.
100. Kagambèga A, Martikainen O, Siitonen A, et al. Prevalence of diarrheagenic Escherichia coli virulence genes in the feces of slaughtered cattle, chickens, and pigs in Burkina Faso. Microbiologyopen. 2012;1:276-284.
101. Nakhjavani FA, Emaneini M, Hosseini H, et al. Molecular analysis of typical and atypical enteropathogenic Escherichia coli (EPEC) isolated from children with diarrhoea. J Med Microbiol. 2013;62: 191-195.
102. Health Protection Agency. Guidance on infection control in schools and other childcare settings. 2010. Available from: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1194947358374. Accessed April 8, 2013.
103. PHLS Advisory Committee on Gastrointestinal Infections. Preventing person-to-person spread following gastrointestinal infections: guidelines for public health physicians and environmental health officers. Commun Dis Public Health. 2004;7:362-384.
104. Patel M, Pedreira C, de Olivieria LH, et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhoea among children in Nicaragua. JAMA. 2009;301:2243-2251.
105. Tate JE, Cortese MM, Payne DC, et al. Uptake, impact, and effectiveness of rotavirus vaccination in the United States: review of the first 3 years of postlicensure data. Pediatr Infect Dis J. 2011;30:S56-S60.
106. Munos MK, Walker CL, Black RE. The effect of rotavirus vaccine on diarrhea mortality. Int J Epidemiol. 2010;39:i56-i62.
107. Vesikari T, Van Damme P, Giaquinto C, et al. European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe. J Pediatr Gastroenterol Nutr. 2008;46:S38-S48.
108. Parashar UD, Alexander JP, Glass RI. Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55:1-13.
109. Khin MU, Nyunt Nyunt-Wai, et al. Effect on clinical outcome of breast feeding during acute diarrhoea. Br Med J (Clin Res Ed). 1985;290:587-589.
110. Casburn-Jones AC, Farthing MJG. Management of infectious diarrhoea. Gut. 2004;53:296-305.
111. Walker A. Breast milk as the gold standard for protective nutrients. J Pediatr. 2010;156:S3-S7.
112. Plenge-Bönig A, Soto-Ramírez N, Karmaus W, Petersen G, Davis S, Forster J. Breastfeeding protects against acute gastroenteritis due to rotavirus in infants. Eur J Pediatr. 2010;169:1471-1476.
113. Ladomenou F, Moschandreas J, Kafatos A, Tselentis Y, Galanakis E. Protective effect of exclusive breastfeeding against infections during infancy: a prospective study. Arch Dis Child. 2010;95: 1004-1008.
114. Caramia G. Gastroenteric pathology and probiotics: from myth to scientific evidence. Current aspects. Minerva Gastroenterol Dietol. 2009;55:237-272.
115. Caramia G, Silvi S. Probiotics: from the ancient wisdom to the actual therapeutical and nutraceutical perspective. In: Malago JJ, Koninkx JFJG, Marinsek-Logar R. Probiotic Bacteria and Enteric Infections: Cytoprotection by Probiotic Bacteria. Heidelberg: Springer; 2011: 3-38.
116. Allen SJ, Martinez EG, Gregorio GV, Dans LF. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. 2010;11:CD003048.
117. Rojas MA, Lozano JM, Rojas MX, et al. Prophylactic probiotics to prevent death and nosocomial infection in preterm infants. Pediatrics. 2012;130:e1113-e1120.
118. World Health Organization. First Steps for Managing an Outbreak of Acute Diarrhea. Geneva: WHO; 2004. Available from: http://www.who.int/topics/cholera/publications/en/first_steps.pdf. Accessed April 8, 2013.
119. Ognio LS. Protocolo de Vigilancia Epidemiológica de Cólera. Lima: Oficina General de Epidemiologia, Ministério de Salud de Peru; 2006.
120. Murphy C, Hahn S, Volmink J. Reduced osmolarity oral rehydration solution for treating cholera. Cochrane Database Syst Rev. 2004;4:CD003754.
121. Hirschhorn NJ, Kinzie JL, Sachar DB, et al. Decrease in net stool output in cholera during intestinal perfusion with glucose-containing solutions. N Engl J Med. 1968;279:176-181.
122. Pierce NF, Sack RB, Mitra RC, et al. Replacement of water and electrolyte losses in cholera by an oral glucose-electrolyte solution. Ann Intern Med. 1969;70:1173-1181.
123. MacKenzie A, Barnes G. Randomized controlled trial comparing oral and intravenous rehydration therapy in children with diarrhea. BMJ. 1991;303:393-396.
124. Hartling L, Bellemare S, Wiebe N, et al. Oral versus intravenous rehydration for treating dehydration due to gastroenteritis in children. Cochrane Database of Syst Rev. 2006;3: CD004390.
125. Caramia G, Pompilio A, Ciuccarelli F, et al. Dehydration and rehydration. State of the art and therapeutic interventions. Prog Nutr. 2003;5(4):299-313.
126. Ali SA, Hill DR. Giardia intestinalis. Curr Opin Infect Dis. 2003;16: 453-460.
127. Fabiani E, Catassi C, Vignini M, et al. La gastroenterite acuta: reidratazione, alimentazione e terapia al pronto soccorso. In: Tavola Rotonda. La Gastroenterite Acuta: Reidratazione, Alimentazione, Terapia; 2005.
128. Rautenberg TA, Zerwes U, Foerster D, Aultman R. Evaluating the cost utility of racecadotril for the treatment of acute watery diarrhea in children: the RAWD model. Clinicoecon Outcomes Res. 2012;4: 109-116.
129. Lehert P, Chéron G, Calatayud GA, et al. Racecadotril for childhood gastroenteritis: an individual patient data meta-analysis. Dig Liver Dis. 2011;43:707-713.
130. Salazar-Lindo E, Santisteban-Ponce J, Chea-Woo E, Gutierrez M. Racecadotril in the treatment of acute watery diarrhea in children. N Engl J Med. 2000;343:463-467.
131. Cézard JP, Duhamel JF, Meyer M, et al. Efficacy and tolerability of racecadotril in acute diarrhea in children. Gastroenterology. 2001;120: 799-805.
132. Sturm JJ, Pierzchala A, Simon HK, Hirsh DA. Ondansetron use in the pediatric emergency room for diagnoses other than acute gastroenteritis. Pediatr Emerg Care. 2012;28:247-250.
133. Fedorowicz Z, Jagannath VA, Carter B. Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents. Cochrane Database Syst Rev. 2011;9:CD005506.
134. Freedman SB, Adler M, Seshadri R, Powell EC. Oral ondansetron for gastroenteritis in a pediatric emergency department. N Engl J Med. 2006;354:1698-1705.
135. Ramsook C, Sahagun-Carreon I, Kozinetz CA, Moro-Sutherland D. A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis. Ann Emerg Med. 2002;39:397-403.
136. World Health Organization. Unedited Draft Report of the 17th Expert Committee on the Selection and Use of Essential Medicines. Geneva: WHO; 2009. Available from: http://www.who.int/selection_medicines/committees/expert/17/WEBuneditedTRS_2009.pdf. Accessed April 8, 2013.
137. Prasad AS. Discovery of human zinc deficiency: 50 years later. J Trace Elem Med Biol. 2012;26:66-69.
138. Lazzerini M, Ronfani L. Oral zinc for treating diarrhoea in children. Cochrane Database Syst Rev. 2012;6:CD005436.
139. Kouame KS, Verga ME, Pittet A, et al. Zinc and diarrhea in children under 5 years: WHO recommendations implemented in Switzerland. Rev Med Suisse. 2012;8:1244-1247. French.
140. Allen SJ, Okoko B, Martinez E, et al. Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev. 2004;2:CD003048.
141. Szajewska H. Probiotics and prebiotics in pediatrics: where are we now? Turk J Pediatr. 2007;49:231-244.
142. Szajewska H, Skorka A, Dylag M. Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children. Aliment Pharmacol Ther. 2007;25:257-264.
143. Francavilla R, Lionetti E, Castellaneta S, et al. Randomised clinical trial: Lactobacillus reuteri DSM 17938 vs placebo in children with acute diarrhea-a double-blind study. Aliment Pharmacol Ther. 2012;36:363-369.
144. Hajela N, Nair GB, Abraham P, Ganguly NK. Health impact of probiotics-vision and opportunities. Gut Pathog. 2012;4:1.
145. Guandalini S. Probiotics for children with diarrhea: an update. J Clin Gastroenterol. 2008;42 Suppl 2:S53-S57.
146. Lin YP, Thibodeaux CH, Peña JA, et al. Probiotic Lactobacillus reuteri suppress proinflammatory cytokines via c-Jun. Inflamm Bowel Dis. 2008;14:1068-1083.
147. Thomas CM, Hong T, van Pijkeren JP, et al. Histamine derived from probiotic Lactobacillus reuteri suppresses TNF via modulation of PKA and ERK signaling. PLoS One. 2012;7: e31951.
148. Phavichitr N, Catto-Smith A. Acute gastroenteritis in children: what role for antibacterials? Paediatr Drugs. 2003;5:279-290.
149. Onwuezobe IA, Oshun PO, Odigwe CC. Antimicrobials for treating symptomatic non-typhoidal Salmonella infection. Cochrane Database Syst Rev. 2012;11:CD001167.
150. Pfeiffer ML, DuPont HL, Ochoa TJ. The patient presenting with acute dysentery-a systematic review. J Infect. 2012;64:374-386.
151. Maetz B, Abbou R, Andreoletti JB, Bruant-Rodier C. Infections following the application of leeches: two case reports and review of the literature. J Med Case Rep. 2012;6:364.
152. Wilmer A, Slater K, Yip J, et al. The role of leech water sampling in choice of prophylactic antibiotics in medical leech therapy. Microsurgery. Epub February 18, 2013.
153. Maragkoudakis S, Poulidaki SR, Papadomanolaki E, et al. Empiric antimicrobial therapy and infectious diarrhea. Do we need local guidelines? Eur J Intern Med. 2011;22:e60-e62.
154. Iovine NM. Resistance mechanisms in Campylobacter jejuni. Virulence. 2013;4:230-240.
155. Khalaf N, Crews JD, DuPont HL, Koo HL. Clostridium difficile: an emerging pathogen in children. Discov Med. 2012;14: 105-113.
156. Valerio M, Pedromingo M, Muñoz P, et al. Potential protective role of linezolid against Clostridium difficile infection. Int J Antimicrob Agents. 2012;39:414-419.
157. Whitman CB, Czosnowski QA. Fidaxomicin for the treatment of Clostridium difficile infections. Ann Pharmacother. 2012;46: 219-228.
158. Khanna S, Pardi DS. Clostridium difficile infection: new insights into management. Mayo Clin Proc. 2012;87:1106-1117.
159. Foglia G, Shah S, Luxemburger C, Pietrobon PJ. Clostridium difficile: development of a novel candidate vaccine. Vaccine. 2012;30: 4307-4309.
160. Al Jarousha AM, El Jarou MA, El Qouqa IA. Bacterial enteropathogens and risk factors associated with childhood diarrhea. Indian J Pediatr. 2011;78:165-170.
161. Behiry IK, Abada EA, Ahmed EA, Labeeb RS. Enteropathogenic Escherichia coli associated with diarrhea in children in Cairo, Egypt. ScientificWorldJournal. 2011;11:2613-2619.
162. Ochoa TJ, Contreras CA. Enteropathogenic Escherichia coli infection in children. Curr Opin Infect Dis. 2011;24:478-483.
163. la Cabada Bauche J, Dupont HL. New developments in traveler's diarrhea. Gastroenterol Hepatol (N Y). 2011;7:88-95.
164. McGannon CM, Fuller CA, Weiss AA. Different classes of antibiotics differentially influence shiga toxin production. Antimicrob Agents Chemother. 2010;54:3790-3798.
165. Nitschke M, Sayk F, Härtel C, et al. Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4. JAMA. 2012;307:1046-1052.
166. Hauswaldt S, Nitschke M, Sayk F, et al. Lessons learned from outbreaks of Shiga toxin producing Escherichia coli. Curr Infect Dis Rep. 2013;15:4-9.
167. Rund SA, Rohde H, Sonnenborn U, Oelschlaeger TA. Antagonistic effects of probiotic Escherichia coli Nissle 1917 on EHEC strains of serotype O104:H4 and O157:H7. Int J Med Microbiol. 2013; 303:1-8.
168. Moriel DG, Rosini R, Seib KL, et al. Escherichia coli: great diversity around a common core. MBio. 2012;3:e00118-e00112.
169. Ahmad K, Fatemeh F, Mehri N, Maryam S. Probiotics for the treatment of pediatric Helicobacter pylori infection: a randomized double blind clinical trial. Iran J Pediatr. 2013;23:79-84.
170. Brigic E, Hadzic D, Mladina N. Childhood and Coress model of carcinogenesis. Med Arh. 2012;66:375-377.
171. Morgan DR, Torres J, Sexton R, et al. Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. JAMA. 2013;309:578-586.
172. World Health Organization. Guidelines for the Control of Shigellosis, Including the Epidemics Which Were Caused by Shigella dysenteriae Type 1. Geneva: WHO; 2005.
173. Christopher PR, David KV, John SM, Sankarapandian V. Antibiotic therapy for Shigella dysentery. Cochrane Database Syst Rev. 2010;8: CD006784.
174. Von Seidlein L, Kim DR, Ali M, et al. A multi centre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology. PLoS Med. 2006;3:e353.
175. Mandal JVG, Emelda JSM, Parija SC. The recent trends of shigellosis: a JIPMER perspective. J Clin Diagn Res. 2012;6:1474-1477.
176. Martinez-Becerra FJ, Kissmann JM, Diaz-McNair J, et al. Broadly protective Shigella vaccine based on type III secretion apparatus proteins. Infect Immun. 2012;80:1222-1231.
177. Adagbada AO, Adesida SA, Nwaokorie FO, Niemogha MT, Coker AO. Cholera epidemiology in Nigeria: an overview. Pan Afr Med J. 2012;12:59.
178. Mandal J, Dinoop KP, Parija SC, et al. Increasing antimicrobial resistance of Vibrio cholerae OI biotype E1 tor strains isolated in a tertiary-care centre in India. J Health Popul Nutr. 2012;30:12-16.
179. Huovinen E, Sihvonen LM, Virtanen MJ, Symptoms and sources of Yersinia enterocolitica-infection: a case-control study. BMC Infect Dis. 2010;10:122.
180. Carniel E, Hinnebush BJ. Yersinia: Molecular and Cellular Biology. Wymondham, UK: Horizon Bioscience; 2004.
181. Manzoni P, Mostert M, Latino MA, et al. Clinical characteristics and response to prophylactic fluconazole of preterm VLBW neonates with baseline and acquired fungal colonisation in NICU: data from a multicentre RCT. Early Hum Dev. 2012;88 Suppl 2:S60-S64.
182. Ramos Amador JT, Prieto Tato L, Guillén Martín S. Why might micafungin be the drug of choice in pediatric patients? Enferm Infecc Microbiol Clin. 2011;29 Suppl 2:23-28.
183. Hope WW, Smith PB, Arrieta A, et al. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother. 2010;54:2633-2637.
184. Montejo M, Quindòs G. Scientific evidence supporting the use of micafungin in the treatment of invasive candidiasis. Enferm Infecc Microbiol Clin. 2011;29 Suppl 2:15-22.
185. Manzoni P, Benjamin DK, Franco C, et al. Echinocandins for the nursery: an update. Curr Drug Metab. 2013;14:203-207.
186. Scott LJ. Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections. Drugs. 2012;72:2141-2165.
187. Debnath A, Ndao M, Reed SL. Reprofiled drug targets ancient protozoans: drug discovery for parasitic diarrheal diseases. Gut Microbes. 2013;4:66-71.
188. Rossignol JF, Lopez-Chegne N, Julcamoro LM, et al. Nitazoxanide for the empiric treatment of pediatric infectious diarrhea. Trans R Soc Trop Med Hyg. 2012;106:167-173.
189. Granados CE, Reveiz L, Uribe LG, Criollo CP. Drugs for treating giardiasis. Cochrane Database Syst Rev. 2012;12:CD007787.
190. Tejman-Yarden N, Miyamoto Y, Leitsch D, et al. A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia. Antimicrob Agents Chemother. Epub February 12, 2013.
191. Chacín-Bonilla L. Current pharmacotherapy of amebiasis, advances in new drugs, and design of a vaccine. Invest Clin. 2012;53: 301-314.
192. Prichard RK, Basáñez MG, Boatin BA, et al. A research agenda for helminth diseases of humans: intervention for control and elimination. PLoS Negl Trop Dis. 2012;6:e1549.
193. Speich B, Ame SM, Ali SM, et al. Efficacy and safety of nitazoxanide, albendazole, and nitazoxanide-albendazole against Trichuris trichiura infection: a randomized controlled trial. PLoS Negl Trop Dis. 2012;6:e1685.